SCHEMBL5543907

SCHEMBL5543907

CC1(C)Oc2ccc([O])cc2C1=O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.37
PPIB P23284 1/20 0.35
HTT P42858 2/20 0.34
GAA P10253 2/20 0.34
TSHR P16473 1/20 0.34
KDM4E B2RXH2 11/20 0.33
ATM Q13315 2/20 0.33
RAD52 P43351 1/20 0.33
ALDH1A1 P00352 7/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HPGD P15428 5/20 0.32
TDP1 Q9NUW8 1/20 0.31
KLK7 P49862 1/20 0.31
HSD17B10 Q99714 2/20 0.30
GLA P06280 1/20 0.30
CASP1 P29466 1/20 0.30
CASP7 P55210 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2433995 0.79 PPOX (0.41) MAPTKDM4EALDH1A1HPGDTDP1
SCHEMBL5543912 0.79 MAPT (0.58) MAPTKDM4EALDH1A1L3MBTL1
SCHEMBL23362956 0.79 CA1 (0.43) MAPTTDP1L3MBTL1
SCHEMBL29804089 0.79 CA1 (0.43) MAPTTDP1L3MBTL1
SCHEMBL506797 0.75 CA12 (0.36) MAPTPPIBHTTGAATSHR
SCHEMBL11946799 0.73 HTR7 (0.38) MAPTKDM4EATMALDH1A1SMN1; SMN2
SCHEMBL11190288 0.71 PTGS2 (0.50) MAPTTSHRHPGD
SCHEMBL22984253 0.70 PARP1 (0.36) GAATSHRKDM4EATMALDH1A1
SCHEMBL12686308 0.69 TGM2 (0.40) MAPTPPIBHTTGAATSHR
SCHEMBL12478389 0.69 S100A4 (0.42) MAPTTDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885PPIB 3759/4885HTT 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.